0000000000088926

AUTHOR

Olaf Hoffmann

showing 2 related works from this author

Systematic monitoring for detection of atrial fibrillation in patients with acute ischaemic stroke (MonDAFIS): a randomised, open-label, multicentre …

2021

Summary Background Systematic electrocardiogram (ECG) monitoring improves detection of covert atrial fibrillation in stroke survivors but the effect on secondary prevention is unknown. We aimed to assess the effect of systematic ECG monitoring of patients in hospital on the rate of oral anticoagulant use after 12 months. Methods In this investigator-initiated, randomised, open-label, parallel-group multicentre study with masked endpoint adjudication, we recruited patients aged at least 18 years with acute ischaemic stroke or transient ischaemic attack without known atrial fibrillation in 38 certified stroke units in Germany. Patients were randomly assigned (1:1) to usual diagnostic procedur…

Malemedicine.medical_specialtyepidemiology [Atrial Fibrillation]methods [Electrocardiography]Populationdiagnosis [Ischemic Stroke]030204 cardiovascular system & hematologyBrain Ischemia03 medical and health sciencesElectrocardiography0302 clinical medicineRisk FactorsInternal medicineIschaemic strokeAtrial Fibrillationdiagnosis [Brain Ischemia]medicineepidemiology [Brain Ischemia]HumansIn patientMyocardial infarctionddc:610educationepidemiology [Ischemic Stroke]Ischemic StrokeMonitoring PhysiologicAgedAged 80 and overeducation.field_of_studybusiness.industryphysiopathology [Ischemic Stroke]Hazard ratiodiagnosis [Atrial Fibrillation]Atrial fibrillationOdds ratioMiddle Agedmethods [Monitoring Physiologic]medicine.diseasephysiopathology [Atrial Fibrillation]physiopathology [Brain Ischemia]3. Good healthFemaleNeurology (clinical)Open labelbusiness030217 neurology & neurosurgery
researchProduct

Multiple Sclerosis Therapy Consensus Group (MSTCG): position statement on disease-modifying therapies for multiple sclerosis (white paper)

2021

Multiple sclerosis is a complex, autoimmune-mediated disease of the central nervous system characterized by inflammatory demyelination and axonal/neuronal damage. The approval of various disease-modifying therapies and our increased understanding of disease mechanisms and evolution in recent years have significantly changed the prognosis and course of the disease. This update of the Multiple Sclerosis Therapy Consensus Group treatment recommendation focuses on the most important recommendations for disease-modifying therapies of multiple sclerosis in 2021. Our recommendations are based on current scientific evidence and apply to those medications approved in wide parts of Europe, particular…

Position statementmedicine.medical_specialtytreatment recommendationMedizin610 Medicine & healthReviewDiseasemultiple sclerosis03 medical and health sciences0302 clinical medicineWhite paperNeuronal damagemedicine030212 general & internal medicineRC346-429610 Medicine & healthIntensive care medicinePharmacologybusiness.industryMultiple sclerosisDisease mechanismsGuidelinemedicine.diseasedisease-modifying therapy3. Good healthGroup treatmentNeurologyNeurology. Diseases of the nervous systemNeurology (clinical)businessguideline030217 neurology & neurosurgeryTherapeutic Advances in Neurological Disorders
researchProduct